Genedrive shares jump on NICE test recommendation
3rd Apr 2024 13:54
(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.
Read moreGenedrive receives R&D tax credit, plans fundraise
15th Mar 2024 14:27
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to £1.2m.
Read moreGenedrive set to apply for NICE EVA funding
19th Feb 2024 10:56
(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).
Read moreGenedrive confirms £0.6m equity prepayment drawdown
2nd Jan 2024 14:39
(Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.
Read moreGenedrive gets first product orders from several countries
20th Dec 2023 13:57
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive has received its first orders for Genedrive MT-RNR1 products from several countries, it announced on Wednesday, including France, Austria, Greece, Saudi Arabia, Turkey, and the Netherlands.
Read moreGenedrive diagnostic test system gets UKCA registration
6th Sep 2023 13:55
(Sharecast News) - Point-of-care molecular diagnostics developer Genedrive announced on Wednesday that its Genedrive CYP2C19 System has received UKCA marking registration.
Read moreGenedrive draws down £0.3m under equity prepayment facility
5th Jul 2023 14:41
(Sharecast News) - Molecular diagnostics company Genedrive announced the latest drawdown of £0.3m under its £5m equity prepayment facility on Wednesday.
Read moreGenedrive secures multi-partner grant award
16th Jun 2023 10:49
(Sharecast News) - Molecular diagnostics specialist Genedrive announced its involvement in a multi-partner grant award called DEVOTE on Friday, supported by Innovate UK and the UK government's Innovation Accelerator programme.
Read moreGenedrive jumps on draft NICE testing guidance
19th May 2023 16:03
(Sharecast News) - Point-of-care molecular diagnostics company Genedrive announced on Friday that the UK's National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of CYP2C19 genotyping before administering clopidogrel in the management of ischemic stroke (IS) patients.
Read moreGenedrive engages with US FDA over infant test
5th Oct 2022 11:03
(Sharecast News) - Near-patient molecular diagnostics company Genedrive has started engaging with the US Food and Drug Administration (FDA), it announced on Wednesday, to progress the regulatory approval of its 'MT-RNR1 ID Kit' into the United States.
Read moreGenedrive test to go through new, faster NICE process
26th Sep 2022 14:10
(Sharecast News) - Molecular diagnostics technology company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has transferred the evaluation of its 'MT-RNR1' test to a new 'early value assessment programme'.
Read moreAnother Genedrive test to be assessed by NICE
22nd Aug 2022 10:39
(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has started an evaluation of CYP2C19 genotype testing for clopidogrel treatment, via a new NICE diagnostics assessment programme (DAP).
Read moreGenedrive test to be evaluated by NICE
16th Jun 2022 14:42
(Sharecast News) - Molecular diagnostics company Genedrive announced on Thursday that the UK's National Institute for Health and Clinical Excellence (NICE) has started an evaluation of the Genedrive MT-RNR1 test, via its Diagnostics Assessment Programme (DAP).
Read moreGenedrive rallies on positive news about hearing loss test
29th Mar 2022 13:04
(Sharecast News) - Molecular diagnostics company Genedrive rallied on Tuesday after the UK's National Institute of Clinical Excellence (NICE) issued a new Medtech Innovation Briefing on its MT-RNR1 hearing loss test.
Read moreGenedrive finance chief announces April departure
2nd Mar 2022 14:57
(Sharecast News) - Molecular diagnostics company Genedrive said on Wednesday that its chief financial officer Matthew Fowler would be leaving it and stepping down from the board on 19 April.
Read more